ArticleWorld journal of surgical oncology2026
An LSCC-specific R-loop-related model predicts prognosis and neoadjuvant immunotherapy response and identifies EIF5A2-mediated tumor-immune crosstalk.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) lacks robust biomarkers for prognostic stratification and immunotherapy prediction. R-loops have been increasingly implicated in transcriptional dysregulation and tumor progression, but their clinical significance in LSCC remains unclear.
methodsWe generated an LSCC-specific R-loop-related gene set by intersecting R-loop-associated genes with differentially expressed genes in the TCGA-LSCC cohort, and constructed a prognostic model using LASSO-Cox regression. The model was externally validated in GSE25727 and GSE27020 and further evaluated for neoadjuvant immunotherapy relevance in GSE210287. Single-cell RNA sequencing data from GSE290927 were used to identify the core immune-regulatory gene within the model and explore its potential mechanism in tumor-immune interaction.
resultsWe identified 56 LSCC-specific R-loop-related candidate genes and established a three-gene model that successfully stratified patients into distinct risk groups, with stable performance in external validation cohorts. The model retained prognostic value, distinguished different immune microenvironment states, and was associated with neoadjuvant immunotherapy response. Among the model genes, EIF5A2 showed the greatest consistency with the overall model in terms of high-risk association, poor prognosis, and unfavorable immune-related changes, and was therefore identified as the core gene. Single-cell analysis further showed that EIF5A2 was mainly expressed in tumor cells, while cell-cell communication analysis revealed enhanced interactions between EIF5A2-high tumor cells and exhausted CD8 T cells, with MIF-CD74-related signaling representing the dominant ligand-receptor axis.
conclusionsWe established an LSCC-specific R-loop-related model with value in prognostic stratification and neoadjuvant immunotherapy prediction, and further identified EIF5A2 as a core immune-regulatory gene within the model. These findings provide a biologically interpretable framework linking R-loop-related tumor states to prognosis, immunotherapy response, and immune remodeling in LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.